As part of a new research deal with Celgene Corp., a startup with intriguing technology that could someday enable personalized medicine by letting doctors test different cancer drugs in a ...
Read more
March 2 (Reuters) - Celgene Corp's experimental drug apremilast proved to be more effective than a dummy pill for psoriasis patients in a late-stage study, clearing the way for the ...
Read more
(Reuters) - Celgene Corp on Monday said its drug Revlimid won full regulatory approval in China for patients with relapsed or refractory multiple myeloma, a type of cancer that starts ...
Read more
January 23, 2013 10:32 am by Berkrot, Bill | 0 Comments
(Reuters) - Celgene Corp said its Abraxane drug helped patients with advanced pancreatic cancer live an average of two months longer than chemotherapy and significantly increased the percentage of those ...
Read more
(Reuters) - Celgene Corp said on Friday that a clinical trial of Abraxane, its drug to treat breast and lung cancer, improved survival in patients with pancreatic cancer.The company did ...
Read more
(Reuters) - Independent safety monitors determined that Celgene Corp's experimental cancer drug met the main goal of a late stage trial of improving progression-free survival in multiple myeloma patients who ...
Read more
U.S. health regulators on Friday widened the approved use of Celgene Corp's breast cancer drug Abraxane to include treatment for non-small cell lung cancer, the most common form of lung ...
Read more
(Reuters) - Celgene Corp said a late-stage trial of its cancer drug Abraxane met its main goal of improving the patient's time of survival without worsening skin cancer, when compared ...
Read more
Celgene’s (NASDAQ:CELG) move to withdraw its multiple myeloma drug Revlimid new application submission from the Committee for Medicinal Products for Human Use was a setback for the drug developer. But ...
Read more
Celgene (NASDAQ:CELG) has submitted a new drug application to the U.S. Food and Drug Administration for pomalidomide, a drug designed for multiple myeloma that does not respond to therapies.Since the ...
Read more
Celgene (NASDAQ:CELG) has agreed to a strategic discovery deal with a company that is developing antibodies to combat multiple diseases in Celgene’s latest move to diversify its portfolio.AnaptysBio uses a ...
Read more
February 9, 2012 11:27 am by Stephanie Baum | 0 Comments
Celgene (NYSE:CELG) has made a $15 million strategic investment in a cancer drug developer, which gives it a seat on the company’s board and opens up collaboration opportunities down the ...
Read more
Celgene (NYSE:CELG) has acquired cancer drug developer Avila Therapeutics in a deal valued up to $925 million if milestones are reached.Avila’s therapeutic platform involves the development of covalent drugs, which ...
Read more
The CEO of Memorial Sloane-Kettering Cancer Research Center is the focus of a $1 billion lawsuit filed by a cancer research institute at the University of Pennsylvania for allegedly stealing ...
Read more
December 23, 2011 8:30 am by Stephanie Baum | 0 Comments
New Jersey Gov. Chris Christie’s chief of staff is returning to the pharmaceutical industry in a newly created position with Celgene (NASDAQ: CELG) next month.Richard Bagger will serve as senior ...
Read more
